nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Ticagrelor—coronary artery disease	0.462	1	CiPCiCtD
Vemurafenib—ALB—coronary artery disease	0.0556	1	CbGaD
Vemurafenib—ORM1—Penbutolol—coronary artery disease	0.0307	0.0987	CbGbCtD
Vemurafenib—ORM1—Pitavastatin—coronary artery disease	0.0268	0.0863	CbGbCtD
Vemurafenib—ABCC1—Rosuvastatin—coronary artery disease	0.018	0.058	CbGbCtD
Vemurafenib—ABCG2—Pitavastatin—coronary artery disease	0.0164	0.0527	CbGbCtD
Vemurafenib—ABCG2—Telmisartan—coronary artery disease	0.0164	0.0527	CbGbCtD
Vemurafenib—ABCC1—Atorvastatin—coronary artery disease	0.0149	0.0481	CbGbCtD
Vemurafenib—ABCG2—Ezetimibe—coronary artery disease	0.0121	0.0388	CbGbCtD
Vemurafenib—ABCG2—Rosuvastatin—coronary artery disease	0.0121	0.0388	CbGbCtD
Vemurafenib—ALB—Pitavastatin—coronary artery disease	0.0113	0.0363	CbGbCtD
Vemurafenib—ABCG2—Pravastatin—coronary artery disease	0.011	0.0353	CbGbCtD
Vemurafenib—ALB—Valsartan—coronary artery disease	0.011	0.0353	CbGbCtD
Vemurafenib—CYP1A2—Gemfibrozil—coronary artery disease	0.00891	0.0287	CbGbCtD
Vemurafenib—ALB—Rosuvastatin—coronary artery disease	0.00832	0.0268	CbGbCtD
Vemurafenib—ALB—Acetylsalicylic acid—coronary artery disease	0.00811	0.0261	CbGbCtD
Vemurafenib—ALB—Captopril—coronary artery disease	0.00801	0.0258	CbGbCtD
Vemurafenib—CYP1A2—Clopidogrel—coronary artery disease	0.00772	0.0248	CbGbCtD
Vemurafenib—CYP3A4—Ticagrelor—coronary artery disease	0.00655	0.0211	CbGbCtD
Vemurafenib—ALB—Furosemide—coronary artery disease	0.00644	0.0207	CbGbCtD
Vemurafenib—ALB—Losartan—coronary artery disease	0.00631	0.0203	CbGbCtD
Vemurafenib—CYP3A4—Fenofibrate—coronary artery disease	0.00584	0.0188	CbGbCtD
Vemurafenib—CYP2D6—Niacin—coronary artery disease	0.00482	0.0155	CbGbCtD
Vemurafenib—CYP3A4—Gemfibrozil—coronary artery disease	0.00467	0.015	CbGbCtD
Vemurafenib—CYP2D6—Timolol—coronary artery disease	0.00448	0.0144	CbGbCtD
Vemurafenib—CYP3A4—Clopidogrel—coronary artery disease	0.00405	0.013	CbGbCtD
Vemurafenib—CYP2D6—Captopril—coronary artery disease	0.00395	0.0127	CbGbCtD
Vemurafenib—CYP2D6—Simvastatin—coronary artery disease	0.00381	0.0123	CbGbCtD
Vemurafenib—CYP1A2—Losartan—coronary artery disease	0.00377	0.0121	CbGbCtD
Vemurafenib—CYP3A4—Eplerenone—coronary artery disease	0.00376	0.0121	CbGbCtD
Vemurafenib—CYP2D6—Pravastatin—coronary artery disease	0.00373	0.012	CbGbCtD
Vemurafenib—CYP2D6—Lovastatin—coronary artery disease	0.00373	0.012	CbGbCtD
Vemurafenib—CYP2D6—Atorvastatin—coronary artery disease	0.0034	0.0109	CbGbCtD
Vemurafenib—CYP3A4—Enalapril—coronary artery disease	0.00335	0.0108	CbGbCtD
Vemurafenib—CYP3A4—Rosuvastatin—coronary artery disease	0.00261	0.00839	CbGbCtD
Vemurafenib—CYP3A4—Ezetimibe—coronary artery disease	0.00261	0.00839	CbGbCtD
Vemurafenib—CYP3A4—Simvastatin—coronary artery disease	0.00242	0.0078	CbGbCtD
Vemurafenib—CYP3A4—Lovastatin—coronary artery disease	0.00237	0.00763	CbGbCtD
Vemurafenib—CYP3A4—Pravastatin—coronary artery disease	0.00237	0.00763	CbGbCtD
Vemurafenib—CYP3A4—Atorvastatin—coronary artery disease	0.00216	0.00695	CbGbCtD
Vemurafenib—CYP3A4—Losartan—coronary artery disease	0.00198	0.00636	CbGbCtD
Vemurafenib—Etoricoxib—MAPK14—coronary artery disease	0.00189	0.771	CrCbGaD
Vemurafenib—Etoricoxib—CYP2C19—coronary artery disease	0.000347	0.141	CrCbGaD
Vemurafenib—Etoricoxib—PTGS2—coronary artery disease	0.000216	0.088	CrCbGaD
Vemurafenib—RAF1—cardiac ventricle—coronary artery disease	0.000129	0.111	CbGeAlD
Vemurafenib—BRAF—heart—coronary artery disease	0.000128	0.11	CbGeAlD
Vemurafenib—RAF1—myocardium—coronary artery disease	0.000122	0.105	CbGeAlD
Vemurafenib—BRAF—blood—coronary artery disease	9.52e-05	0.0817	CbGeAlD
Vemurafenib—RAF1—heart—coronary artery disease	8.5e-05	0.073	CbGeAlD
Vemurafenib—RAF1—cardiovascular system—coronary artery disease	8.02e-05	0.0688	CbGeAlD
Vemurafenib—RAF1—cardiac atrium—coronary artery disease	7.27e-05	0.0624	CbGeAlD
Vemurafenib—RAF1—blood—coronary artery disease	6.34e-05	0.0544	CbGeAlD
Vemurafenib—ABCC1—myocardium—coronary artery disease	6.08e-05	0.0522	CbGeAlD
Vemurafenib—Nausea—Acetylsalicylic acid—coronary artery disease	5.97e-05	0.00067	CcSEcCtD
Vemurafenib—Erythema—Lisinopril—coronary artery disease	5.97e-05	0.000669	CcSEcCtD
Vemurafenib—Malnutrition—Lisinopril—coronary artery disease	5.97e-05	0.000669	CcSEcCtD
Vemurafenib—Pruritus—Eplerenone—coronary artery disease	5.95e-05	0.000668	CcSEcCtD
Vemurafenib—Body temperature increased—Niacin—coronary artery disease	5.95e-05	0.000668	CcSEcCtD
Vemurafenib—Dizziness—Fenofibrate—coronary artery disease	5.94e-05	0.000666	CcSEcCtD
Vemurafenib—Fatigue—Captopril—coronary artery disease	5.93e-05	0.000665	CcSEcCtD
Vemurafenib—Asthenia—Simvastatin—coronary artery disease	5.88e-05	0.00066	CcSEcCtD
Vemurafenib—Diarrhoea—Ezetimibe—coronary artery disease	5.88e-05	0.00066	CcSEcCtD
Vemurafenib—Constipation—Captopril—coronary artery disease	5.88e-05	0.00066	CcSEcCtD
Vemurafenib—Body temperature increased—Pravastatin—coronary artery disease	5.86e-05	0.000657	CcSEcCtD
Vemurafenib—Hypotension—Losartan—coronary artery disease	5.85e-05	0.000657	CcSEcCtD
Vemurafenib—Dysgeusia—Lisinopril—coronary artery disease	5.84e-05	0.000656	CcSEcCtD
Vemurafenib—Dizziness—Clopidogrel—coronary artery disease	5.83e-05	0.000655	CcSEcCtD
Vemurafenib—Decreased appetite—Perindopril—coronary artery disease	5.8e-05	0.000651	CcSEcCtD
Vemurafenib—Pruritus—Simvastatin—coronary artery disease	5.8e-05	0.000651	CcSEcCtD
Vemurafenib—Dizziness—Lovastatin—coronary artery disease	5.8e-05	0.00065	CcSEcCtD
Vemurafenib—Back pain—Lisinopril—coronary artery disease	5.77e-05	0.000648	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Perindopril—coronary artery disease	5.76e-05	0.000647	CcSEcCtD
Vemurafenib—Diarrhoea—Eplerenone—coronary artery disease	5.76e-05	0.000646	CcSEcCtD
Vemurafenib—Fatigue—Perindopril—coronary artery disease	5.75e-05	0.000646	CcSEcCtD
Vemurafenib—Cough—Ramipril—coronary artery disease	5.74e-05	0.000644	CcSEcCtD
Vemurafenib—Constipation—Perindopril—coronary artery disease	5.71e-05	0.000641	CcSEcCtD
Vemurafenib—Vomiting—Fenofibrate—coronary artery disease	5.71e-05	0.00064	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Losartan—coronary artery disease	5.7e-05	0.00064	CcSEcCtD
Vemurafenib—Hypersensitivity—Valsartan—coronary artery disease	5.7e-05	0.00064	CcSEcCtD
Vemurafenib—Body temperature increased—Trandolapril—coronary artery disease	5.69e-05	0.000638	CcSEcCtD
Vemurafenib—Dizziness—Ezetimibe—coronary artery disease	5.68e-05	0.000638	CcSEcCtD
Vemurafenib—Body temperature increased—Enalapril—coronary artery disease	5.67e-05	0.000636	CcSEcCtD
Vemurafenib—Rash—Fenofibrate—coronary artery disease	5.66e-05	0.000635	CcSEcCtD
Vemurafenib—Dermatitis—Fenofibrate—coronary artery disease	5.65e-05	0.000635	CcSEcCtD
Vemurafenib—Decreased appetite—Furosemide—coronary artery disease	5.64e-05	0.000633	CcSEcCtD
Vemurafenib—Headache—Fenofibrate—coronary artery disease	5.62e-05	0.000631	CcSEcCtD
Vemurafenib—Cough—Timolol—coronary artery disease	5.61e-05	0.00063	CcSEcCtD
Vemurafenib—Vomiting—Clopidogrel—coronary artery disease	5.61e-05	0.00063	CcSEcCtD
Vemurafenib—Diarrhoea—Simvastatin—coronary artery disease	5.61e-05	0.000629	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Furosemide—coronary artery disease	5.6e-05	0.000629	CcSEcCtD
Vemurafenib—Myalgia—Ramipril—coronary artery disease	5.6e-05	0.000628	CcSEcCtD
Vemurafenib—Arthralgia—Ramipril—coronary artery disease	5.6e-05	0.000628	CcSEcCtD
Vemurafenib—Fatigue—Furosemide—coronary artery disease	5.59e-05	0.000628	CcSEcCtD
Vemurafenib—Body temperature increased—Telmisartan—coronary artery disease	5.59e-05	0.000627	CcSEcCtD
Vemurafenib—Vomiting—Lovastatin—coronary artery disease	5.57e-05	0.000625	CcSEcCtD
Vemurafenib—Dizziness—Eplerenone—coronary artery disease	5.56e-05	0.000624	CcSEcCtD
Vemurafenib—Rash—Clopidogrel—coronary artery disease	5.56e-05	0.000624	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	5.56e-05	0.000624	CcSEcCtD
Vemurafenib—Dermatitis—Clopidogrel—coronary artery disease	5.56e-05	0.000624	CcSEcCtD
Vemurafenib—Asthenia—Valsartan—coronary artery disease	5.55e-05	0.000623	CcSEcCtD
Vemurafenib—Constipation—Furosemide—coronary artery disease	5.55e-05	0.000623	CcSEcCtD
Vemurafenib—Hypersensitivity—Niacin—coronary artery disease	5.55e-05	0.000622	CcSEcCtD
Vemurafenib—Asthenia—Olmesartan—coronary artery disease	5.53e-05	0.00062	CcSEcCtD
Vemurafenib—Headache—Clopidogrel—coronary artery disease	5.53e-05	0.00062	CcSEcCtD
Vemurafenib—Rash—Lovastatin—coronary artery disease	5.53e-05	0.00062	CcSEcCtD
Vemurafenib—Dermatitis—Lovastatin—coronary artery disease	5.52e-05	0.00062	CcSEcCtD
Vemurafenib—Headache—Lovastatin—coronary artery disease	5.49e-05	0.000616	CcSEcCtD
Vemurafenib—Pruritus—Valsartan—coronary artery disease	5.48e-05	0.000615	CcSEcCtD
Vemurafenib—Myalgia—Timolol—coronary artery disease	5.47e-05	0.000614	CcSEcCtD
Vemurafenib—Arthralgia—Timolol—coronary artery disease	5.47e-05	0.000614	CcSEcCtD
Vemurafenib—Vomiting—Ezetimibe—coronary artery disease	5.47e-05	0.000613	CcSEcCtD
Vemurafenib—Hypersensitivity—Pravastatin—coronary artery disease	5.46e-05	0.000613	CcSEcCtD
Vemurafenib—Pruritus—Olmesartan—coronary artery disease	5.45e-05	0.000612	CcSEcCtD
Vemurafenib—Decreased appetite—Losartan—coronary artery disease	5.44e-05	0.000611	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	5.44e-05	0.00061	CcSEcCtD
Vemurafenib—Body temperature increased—Captopril—coronary artery disease	5.43e-05	0.00061	CcSEcCtD
Vemurafenib—Dizziness—Simvastatin—coronary artery disease	5.42e-05	0.000608	CcSEcCtD
Vemurafenib—Rash—Ezetimibe—coronary artery disease	5.42e-05	0.000608	CcSEcCtD
Vemurafenib—Dermatitis—Ezetimibe—coronary artery disease	5.41e-05	0.000608	CcSEcCtD
Vemurafenib—Asthenia—Niacin—coronary artery disease	5.4e-05	0.000606	CcSEcCtD
Vemurafenib—Fatigue—Losartan—coronary artery disease	5.4e-05	0.000606	CcSEcCtD
Vemurafenib—Headache—Ezetimibe—coronary artery disease	5.39e-05	0.000604	CcSEcCtD
Vemurafenib—Anaphylactic shock—Ramipril—coronary artery disease	5.37e-05	0.000602	CcSEcCtD
Vemurafenib—Constipation—Losartan—coronary artery disease	5.35e-05	0.000601	CcSEcCtD
Vemurafenib—Vomiting—Eplerenone—coronary artery disease	5.35e-05	0.0006	CcSEcCtD
Vemurafenib—Nausea—Fenofibrate—coronary artery disease	5.33e-05	0.000598	CcSEcCtD
Vemurafenib—Pruritus—Niacin—coronary artery disease	5.33e-05	0.000598	CcSEcCtD
Vemurafenib—Asthenia—Pravastatin—coronary artery disease	5.32e-05	0.000597	CcSEcCtD
Vemurafenib—Rash—Eplerenone—coronary artery disease	5.3e-05	0.000595	CcSEcCtD
Vemurafenib—Hypersensitivity—Trandolapril—coronary artery disease	5.3e-05	0.000595	CcSEcCtD
Vemurafenib—Dermatitis—Eplerenone—coronary artery disease	5.3e-05	0.000595	CcSEcCtD
Vemurafenib—Diarrhoea—Valsartan—coronary artery disease	5.3e-05	0.000594	CcSEcCtD
Vemurafenib—Hypersensitivity—Enalapril—coronary artery disease	5.28e-05	0.000593	CcSEcCtD
Vemurafenib—Body temperature increased—Perindopril—coronary artery disease	5.28e-05	0.000592	CcSEcCtD
Vemurafenib—Diarrhoea—Olmesartan—coronary artery disease	5.27e-05	0.000592	CcSEcCtD
Vemurafenib—Headache—Eplerenone—coronary artery disease	5.27e-05	0.000591	CcSEcCtD
Vemurafenib—Nervous system disorder—Ramipril—coronary artery disease	5.26e-05	0.000591	CcSEcCtD
Vemurafenib—Anaphylactic shock—Timolol—coronary artery disease	5.25e-05	0.000589	CcSEcCtD
Vemurafenib—Pruritus—Pravastatin—coronary artery disease	5.24e-05	0.000588	CcSEcCtD
Vemurafenib—Nausea—Clopidogrel—coronary artery disease	5.24e-05	0.000588	CcSEcCtD
Vemurafenib—Skin disorder—Ramipril—coronary artery disease	5.21e-05	0.000585	CcSEcCtD
Vemurafenib—Infection—Timolol—coronary artery disease	5.21e-05	0.000585	CcSEcCtD
Vemurafenib—Vomiting—Simvastatin—coronary artery disease	5.21e-05	0.000585	CcSEcCtD
Vemurafenib—Hypersensitivity—Telmisartan—coronary artery disease	5.21e-05	0.000585	CcSEcCtD
Vemurafenib—Cough—Lisinopril—coronary artery disease	5.21e-05	0.000584	CcSEcCtD
Vemurafenib—Nausea—Lovastatin—coronary artery disease	5.21e-05	0.000584	CcSEcCtD
Vemurafenib—Rash—Simvastatin—coronary artery disease	5.17e-05	0.00058	CcSEcCtD
Vemurafenib—Dermatitis—Simvastatin—coronary artery disease	5.16e-05	0.00058	CcSEcCtD
Vemurafenib—Asthenia—Trandolapril—coronary artery disease	5.16e-05	0.000579	CcSEcCtD
Vemurafenib—Diarrhoea—Niacin—coronary artery disease	5.15e-05	0.000578	CcSEcCtD
Vemurafenib—Nervous system disorder—Timolol—coronary artery disease	5.15e-05	0.000578	CcSEcCtD
Vemurafenib—ALB—heart—coronary artery disease	5.14e-05	0.0442	CbGeAlD
Vemurafenib—Asthenia—Enalapril—coronary artery disease	5.14e-05	0.000577	CcSEcCtD
Vemurafenib—Headache—Simvastatin—coronary artery disease	5.14e-05	0.000576	CcSEcCtD
Vemurafenib—Body temperature increased—Furosemide—coronary artery disease	5.13e-05	0.000576	CcSEcCtD
Vemurafenib—Dizziness—Valsartan—coronary artery disease	5.12e-05	0.000574	CcSEcCtD
Vemurafenib—Nausea—Ezetimibe—coronary artery disease	5.11e-05	0.000573	CcSEcCtD
Vemurafenib—Skin disorder—Timolol—coronary artery disease	5.1e-05	0.000572	CcSEcCtD
Vemurafenib—Dizziness—Olmesartan—coronary artery disease	5.09e-05	0.000572	CcSEcCtD
Vemurafenib—Pruritus—Trandolapril—coronary artery disease	5.09e-05	0.000571	CcSEcCtD
Vemurafenib—Arthralgia—Lisinopril—coronary artery disease	5.08e-05	0.00057	CcSEcCtD
Vemurafenib—Myalgia—Lisinopril—coronary artery disease	5.08e-05	0.00057	CcSEcCtD
Vemurafenib—Asthenia—Telmisartan—coronary artery disease	5.07e-05	0.000569	CcSEcCtD
Vemurafenib—Pruritus—Enalapril—coronary artery disease	5.07e-05	0.000569	CcSEcCtD
Vemurafenib—Diarrhoea—Pravastatin—coronary artery disease	5.07e-05	0.000569	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	5.04e-05	0.000566	CcSEcCtD
Vemurafenib—Hypotension—Ramipril—coronary artery disease	5.02e-05	0.000563	CcSEcCtD
Vemurafenib—Pruritus—Telmisartan—coronary artery disease	5e-05	0.000561	CcSEcCtD
Vemurafenib—Nausea—Eplerenone—coronary artery disease	5e-05	0.000561	CcSEcCtD
Vemurafenib—Dizziness—Niacin—coronary artery disease	4.98e-05	0.000559	CcSEcCtD
Vemurafenib—Body temperature increased—Losartan—coronary artery disease	4.95e-05	0.000555	CcSEcCtD
Vemurafenib—Asthenia—Captopril—coronary artery disease	4.93e-05	0.000554	CcSEcCtD
Vemurafenib—Diarrhoea—Trandolapril—coronary artery disease	4.92e-05	0.000553	CcSEcCtD
Vemurafenib—Vomiting—Valsartan—coronary artery disease	4.92e-05	0.000552	CcSEcCtD
Vemurafenib—Diarrhoea—Enalapril—coronary artery disease	4.9e-05	0.00055	CcSEcCtD
Vemurafenib—Hypotension—Timolol—coronary artery disease	4.9e-05	0.00055	CcSEcCtD
Vemurafenib—Dizziness—Pravastatin—coronary artery disease	4.9e-05	0.00055	CcSEcCtD
Vemurafenib—Vomiting—Olmesartan—coronary artery disease	4.9e-05	0.00055	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ramipril—coronary artery disease	4.89e-05	0.000549	CcSEcCtD
Vemurafenib—Rash—Valsartan—coronary artery disease	4.88e-05	0.000548	CcSEcCtD
Vemurafenib—Dermatitis—Valsartan—coronary artery disease	4.88e-05	0.000547	CcSEcCtD
Vemurafenib—Nausea—Simvastatin—coronary artery disease	4.87e-05	0.000546	CcSEcCtD
Vemurafenib—Anaphylactic shock—Lisinopril—coronary artery disease	4.87e-05	0.000546	CcSEcCtD
Vemurafenib—Pruritus—Captopril—coronary artery disease	4.86e-05	0.000546	CcSEcCtD
Vemurafenib—Rash—Olmesartan—coronary artery disease	4.86e-05	0.000545	CcSEcCtD
Vemurafenib—Dermatitis—Olmesartan—coronary artery disease	4.85e-05	0.000545	CcSEcCtD
Vemurafenib—Headache—Valsartan—coronary artery disease	4.85e-05	0.000544	CcSEcCtD
Vemurafenib—Diarrhoea—Telmisartan—coronary artery disease	4.84e-05	0.000543	CcSEcCtD
Vemurafenib—Infection—Lisinopril—coronary artery disease	4.84e-05	0.000543	CcSEcCtD
Vemurafenib—Headache—Olmesartan—coronary artery disease	4.83e-05	0.000542	CcSEcCtD
Vemurafenib—Asthenia—Perindopril—coronary artery disease	4.79e-05	0.000537	CcSEcCtD
Vemurafenib—Vomiting—Niacin—coronary artery disease	4.79e-05	0.000537	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Timolol—coronary artery disease	4.78e-05	0.000537	CcSEcCtD
Vemurafenib—Hypersensitivity—Furosemide—coronary artery disease	4.78e-05	0.000537	CcSEcCtD
Vemurafenib—Dizziness—Trandolapril—coronary artery disease	4.76e-05	0.000534	CcSEcCtD
Vemurafenib—Rash—Niacin—coronary artery disease	4.75e-05	0.000533	CcSEcCtD
Vemurafenib—Dermatitis—Niacin—coronary artery disease	4.74e-05	0.000532	CcSEcCtD
Vemurafenib—Dizziness—Enalapril—coronary artery disease	4.74e-05	0.000532	CcSEcCtD
Vemurafenib—Skin disorder—Lisinopril—coronary artery disease	4.73e-05	0.000531	CcSEcCtD
Vemurafenib—Pruritus—Perindopril—coronary artery disease	4.72e-05	0.00053	CcSEcCtD
Vemurafenib—Headache—Niacin—coronary artery disease	4.72e-05	0.000529	CcSEcCtD
Vemurafenib—Vomiting—Pravastatin—coronary artery disease	4.71e-05	0.000529	CcSEcCtD
Vemurafenib—Diarrhoea—Captopril—coronary artery disease	4.7e-05	0.000528	CcSEcCtD
Vemurafenib—Dizziness—Telmisartan—coronary artery disease	4.68e-05	0.000525	CcSEcCtD
Vemurafenib—Rash—Pravastatin—coronary artery disease	4.67e-05	0.000524	CcSEcCtD
Vemurafenib—Dermatitis—Pravastatin—coronary artery disease	4.67e-05	0.000524	CcSEcCtD
Vemurafenib—Decreased appetite—Ramipril—coronary artery disease	4.67e-05	0.000524	CcSEcCtD
Vemurafenib—Asthenia—Furosemide—coronary artery disease	4.66e-05	0.000522	CcSEcCtD
Vemurafenib—Headache—Pravastatin—coronary artery disease	4.64e-05	0.000521	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ramipril—coronary artery disease	4.63e-05	0.00052	CcSEcCtD
Vemurafenib—Fatigue—Ramipril—coronary artery disease	4.63e-05	0.000519	CcSEcCtD
Vemurafenib—Hypersensitivity—Losartan—coronary artery disease	4.61e-05	0.000518	CcSEcCtD
Vemurafenib—Nausea—Valsartan—coronary artery disease	4.6e-05	0.000516	CcSEcCtD
Vemurafenib—Pruritus—Furosemide—coronary artery disease	4.59e-05	0.000515	CcSEcCtD
Vemurafenib—Constipation—Ramipril—coronary artery disease	4.59e-05	0.000515	CcSEcCtD
Vemurafenib—Nausea—Olmesartan—coronary artery disease	4.58e-05	0.000514	CcSEcCtD
Vemurafenib—Vomiting—Trandolapril—coronary artery disease	4.58e-05	0.000514	CcSEcCtD
Vemurafenib—Diarrhoea—Perindopril—coronary artery disease	4.57e-05	0.000513	CcSEcCtD
Vemurafenib—Decreased appetite—Timolol—coronary artery disease	4.56e-05	0.000512	CcSEcCtD
Vemurafenib—Vomiting—Enalapril—coronary artery disease	4.56e-05	0.000511	CcSEcCtD
Vemurafenib—Hypotension—Lisinopril—coronary artery disease	4.55e-05	0.000511	CcSEcCtD
Vemurafenib—Dizziness—Captopril—coronary artery disease	4.55e-05	0.00051	CcSEcCtD
Vemurafenib—Rash—Trandolapril—coronary artery disease	4.54e-05	0.000509	CcSEcCtD
Vemurafenib—Dermatitis—Trandolapril—coronary artery disease	4.53e-05	0.000509	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Timolol—coronary artery disease	4.53e-05	0.000508	CcSEcCtD
Vemurafenib—Fatigue—Timolol—coronary artery disease	4.52e-05	0.000508	CcSEcCtD
Vemurafenib—Rash—Enalapril—coronary artery disease	4.52e-05	0.000507	CcSEcCtD
Vemurafenib—Dermatitis—Enalapril—coronary artery disease	4.52e-05	0.000507	CcSEcCtD
Vemurafenib—Headache—Trandolapril—coronary artery disease	4.51e-05	0.000506	CcSEcCtD
Vemurafenib—Vomiting—Telmisartan—coronary artery disease	4.5e-05	0.000504	CcSEcCtD
Vemurafenib—Asthenia—Losartan—coronary artery disease	4.49e-05	0.000504	CcSEcCtD
Vemurafenib—Headache—Enalapril—coronary artery disease	4.49e-05	0.000504	CcSEcCtD
Vemurafenib—Nausea—Niacin—coronary artery disease	4.47e-05	0.000502	CcSEcCtD
Vemurafenib—Rash—Telmisartan—coronary artery disease	4.46e-05	0.0005	CcSEcCtD
Vemurafenib—Dermatitis—Telmisartan—coronary artery disease	4.45e-05	0.0005	CcSEcCtD
Vemurafenib—Diarrhoea—Furosemide—coronary artery disease	4.44e-05	0.000498	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	4.44e-05	0.000498	CcSEcCtD
Vemurafenib—Pruritus—Losartan—coronary artery disease	4.43e-05	0.000497	CcSEcCtD
Vemurafenib—Headache—Telmisartan—coronary artery disease	4.43e-05	0.000497	CcSEcCtD
Vemurafenib—Dizziness—Perindopril—coronary artery disease	4.41e-05	0.000495	CcSEcCtD
Vemurafenib—Nausea—Pravastatin—coronary artery disease	4.4e-05	0.000494	CcSEcCtD
Vemurafenib—ORM1—blood—coronary artery disease	4.38e-05	0.0376	CbGeAlD
Vemurafenib—Vomiting—Captopril—coronary artery disease	4.37e-05	0.000491	CcSEcCtD
Vemurafenib—Rash—Captopril—coronary artery disease	4.33e-05	0.000486	CcSEcCtD
Vemurafenib—Dermatitis—Captopril—coronary artery disease	4.33e-05	0.000486	CcSEcCtD
Vemurafenib—Headache—Captopril—coronary artery disease	4.31e-05	0.000483	CcSEcCtD
Vemurafenib—Dizziness—Furosemide—coronary artery disease	4.29e-05	0.000482	CcSEcCtD
Vemurafenib—Diarrhoea—Losartan—coronary artery disease	4.28e-05	0.000481	CcSEcCtD
Vemurafenib—Nausea—Trandolapril—coronary artery disease	4.27e-05	0.00048	CcSEcCtD
Vemurafenib—Nausea—Enalapril—coronary artery disease	4.26e-05	0.000478	CcSEcCtD
Vemurafenib—ABCC1—heart—coronary artery disease	4.25e-05	0.0365	CbGeAlD
Vemurafenib—Vomiting—Perindopril—coronary artery disease	4.24e-05	0.000476	CcSEcCtD
Vemurafenib—Body temperature increased—Ramipril—coronary artery disease	4.24e-05	0.000476	CcSEcCtD
Vemurafenib—Decreased appetite—Lisinopril—coronary artery disease	4.23e-05	0.000475	CcSEcCtD
Vemurafenib—Rash—Perindopril—coronary artery disease	4.21e-05	0.000472	CcSEcCtD
Vemurafenib—Dermatitis—Perindopril—coronary artery disease	4.2e-05	0.000472	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Lisinopril—coronary artery disease	4.2e-05	0.000472	CcSEcCtD
Vemurafenib—Nausea—Telmisartan—coronary artery disease	4.2e-05	0.000471	CcSEcCtD
Vemurafenib—Fatigue—Lisinopril—coronary artery disease	4.2e-05	0.000471	CcSEcCtD
Vemurafenib—Headache—Perindopril—coronary artery disease	4.18e-05	0.000469	CcSEcCtD
Vemurafenib—Constipation—Lisinopril—coronary artery disease	4.16e-05	0.000467	CcSEcCtD
Vemurafenib—Body temperature increased—Timolol—coronary artery disease	4.15e-05	0.000466	CcSEcCtD
Vemurafenib—Dizziness—Losartan—coronary artery disease	4.14e-05	0.000465	CcSEcCtD
Vemurafenib—Vomiting—Furosemide—coronary artery disease	4.13e-05	0.000463	CcSEcCtD
Vemurafenib—Rash—Furosemide—coronary artery disease	4.09e-05	0.000459	CcSEcCtD
Vemurafenib—Dermatitis—Furosemide—coronary artery disease	4.09e-05	0.000459	CcSEcCtD
Vemurafenib—Nausea—Captopril—coronary artery disease	4.08e-05	0.000458	CcSEcCtD
Vemurafenib—Headache—Furosemide—coronary artery disease	4.07e-05	0.000456	CcSEcCtD
Vemurafenib—Vomiting—Losartan—coronary artery disease	3.98e-05	0.000447	CcSEcCtD
Vemurafenib—Nausea—Perindopril—coronary artery disease	3.96e-05	0.000445	CcSEcCtD
Vemurafenib—Hypersensitivity—Ramipril—coronary artery disease	3.96e-05	0.000444	CcSEcCtD
Vemurafenib—Rash—Losartan—coronary artery disease	3.95e-05	0.000443	CcSEcCtD
Vemurafenib—Dermatitis—Losartan—coronary artery disease	3.94e-05	0.000443	CcSEcCtD
Vemurafenib—Headache—Losartan—coronary artery disease	3.92e-05	0.00044	CcSEcCtD
Vemurafenib—Hypersensitivity—Timolol—coronary artery disease	3.87e-05	0.000434	CcSEcCtD
Vemurafenib—Nausea—Furosemide—coronary artery disease	3.85e-05	0.000433	CcSEcCtD
Vemurafenib—Asthenia—Ramipril—coronary artery disease	3.85e-05	0.000432	CcSEcCtD
Vemurafenib—Body temperature increased—Lisinopril—coronary artery disease	3.85e-05	0.000432	CcSEcCtD
Vemurafenib—Pruritus—Ramipril—coronary artery disease	3.8e-05	0.000426	CcSEcCtD
Vemurafenib—Asthenia—Timolol—coronary artery disease	3.77e-05	0.000423	CcSEcCtD
Vemurafenib—Nausea—Losartan—coronary artery disease	3.72e-05	0.000417	CcSEcCtD
Vemurafenib—Pruritus—Timolol—coronary artery disease	3.71e-05	0.000417	CcSEcCtD
Vemurafenib—Diarrhoea—Ramipril—coronary artery disease	3.67e-05	0.000412	CcSEcCtD
Vemurafenib—ABCC1—cardiac atrium—coronary artery disease	3.63e-05	0.0312	CbGeAlD
Vemurafenib—Diarrhoea—Timolol—coronary artery disease	3.59e-05	0.000403	CcSEcCtD
Vemurafenib—Hypersensitivity—Lisinopril—coronary artery disease	3.59e-05	0.000403	CcSEcCtD
Vemurafenib—Dizziness—Ramipril—coronary artery disease	3.55e-05	0.000398	CcSEcCtD
Vemurafenib—ABCG2—heart—coronary artery disease	3.52e-05	0.0302	CbGeAlD
Vemurafenib—Asthenia—Lisinopril—coronary artery disease	3.49e-05	0.000392	CcSEcCtD
Vemurafenib—Dizziness—Timolol—coronary artery disease	3.47e-05	0.000389	CcSEcCtD
Vemurafenib—Pruritus—Lisinopril—coronary artery disease	3.44e-05	0.000387	CcSEcCtD
Vemurafenib—Vomiting—Ramipril—coronary artery disease	3.41e-05	0.000383	CcSEcCtD
Vemurafenib—Rash—Ramipril—coronary artery disease	3.38e-05	0.00038	CcSEcCtD
Vemurafenib—Dermatitis—Ramipril—coronary artery disease	3.38e-05	0.00038	CcSEcCtD
Vemurafenib—Headache—Ramipril—coronary artery disease	3.36e-05	0.000377	CcSEcCtD
Vemurafenib—Vomiting—Timolol—coronary artery disease	3.34e-05	0.000374	CcSEcCtD
Vemurafenib—Diarrhoea—Lisinopril—coronary artery disease	3.33e-05	0.000374	CcSEcCtD
Vemurafenib—Rash—Timolol—coronary artery disease	3.31e-05	0.000371	CcSEcCtD
Vemurafenib—Dermatitis—Timolol—coronary artery disease	3.31e-05	0.000371	CcSEcCtD
Vemurafenib—Headache—Timolol—coronary artery disease	3.29e-05	0.000369	CcSEcCtD
Vemurafenib—Dizziness—Lisinopril—coronary artery disease	3.22e-05	0.000361	CcSEcCtD
Vemurafenib—Nausea—Ramipril—coronary artery disease	3.19e-05	0.000358	CcSEcCtD
Vemurafenib—ABCC1—blood—coronary artery disease	3.17e-05	0.0272	CbGeAlD
Vemurafenib—Nausea—Timolol—coronary artery disease	3.12e-05	0.00035	CcSEcCtD
Vemurafenib—Vomiting—Lisinopril—coronary artery disease	3.1e-05	0.000347	CcSEcCtD
Vemurafenib—Rash—Lisinopril—coronary artery disease	3.07e-05	0.000345	CcSEcCtD
Vemurafenib—Dermatitis—Lisinopril—coronary artery disease	3.07e-05	0.000344	CcSEcCtD
Vemurafenib—Headache—Lisinopril—coronary artery disease	3.05e-05	0.000342	CcSEcCtD
Vemurafenib—Nausea—Lisinopril—coronary artery disease	2.89e-05	0.000325	CcSEcCtD
Vemurafenib—ABCG2—blood—coronary artery disease	2.62e-05	0.0225	CbGeAlD
Vemurafenib—CYP1A2—blood—coronary artery disease	2.52e-05	0.0217	CbGeAlD
Vemurafenib—CYP3A4—blood—coronary artery disease	1.83e-05	0.0157	CbGeAlD
Vemurafenib—CYP2D6—blood—coronary artery disease	1.8e-05	0.0154	CbGeAlD
Vemurafenib—RAF1—Signaling Pathways—APOA1—coronary artery disease	1.76e-06	2.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—coronary artery disease	1.76e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KDR—coronary artery disease	1.75e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCA1—coronary artery disease	1.75e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—coronary artery disease	1.75e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP11B2—coronary artery disease	1.74e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TXNRD1—coronary artery disease	1.74e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK14—coronary artery disease	1.74e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—coronary artery disease	1.73e-06	2.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—VCAN—coronary artery disease	1.72e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—coronary artery disease	1.71e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC22A3—coronary artery disease	1.71e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALDOA—coronary artery disease	1.71e-06	2.18e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ESR1—coronary artery disease	1.7e-06	2.18e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GGT1—coronary artery disease	1.69e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GOT1—coronary artery disease	1.69e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HADH—coronary artery disease	1.69e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ARNTL—coronary artery disease	1.69e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FN1—coronary artery disease	1.68e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—F2—coronary artery disease	1.68e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6ST—coronary artery disease	1.68e-06	2.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PSMA6—coronary artery disease	1.67e-06	2.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PSMB5—coronary artery disease	1.67e-06	2.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKBIA—coronary artery disease	1.66e-06	2.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DCN—coronary artery disease	1.66e-06	2.12e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—coronary artery disease	1.66e-06	2.12e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—coronary artery disease	1.64e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTGF—coronary artery disease	1.63e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—coronary artery disease	1.63e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—coronary artery disease	1.62e-06	2.07e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMGCR—coronary artery disease	1.62e-06	2.07e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GOT2—coronary artery disease	1.62e-06	2.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALDH2—coronary artery disease	1.61e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—coronary artery disease	1.61e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G2A—coronary artery disease	1.6e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX2—coronary artery disease	1.6e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA2—coronary artery disease	1.6e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—POMC—coronary artery disease	1.6e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—coronary artery disease	1.6e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—coronary artery disease	1.58e-06	2.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SULT1A1—coronary artery disease	1.58e-06	2.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HK1—coronary artery disease	1.58e-06	2.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX4—coronary artery disease	1.58e-06	2.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG5—coronary artery disease	1.58e-06	2.02e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	1.57e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LIPC—coronary artery disease	1.57e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HBA1—coronary artery disease	1.57e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2C19—coronary artery disease	1.57e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3C2A—coronary artery disease	1.57e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—coronary artery disease	1.57e-06	2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HADHA—coronary artery disease	1.56e-06	2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOC3—coronary artery disease	1.56e-06	2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—coronary artery disease	1.55e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LDLR—coronary artery disease	1.55e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—coronary artery disease	1.55e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	1.55e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GSK3B—coronary artery disease	1.55e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTA1—coronary artery disease	1.54e-06	1.97e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—coronary artery disease	1.53e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC9A1—coronary artery disease	1.53e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—POMC—coronary artery disease	1.53e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREB1—coronary artery disease	1.53e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—coronary artery disease	1.53e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPA—coronary artery disease	1.53e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—coronary artery disease	1.52e-06	1.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCLC—coronary artery disease	1.52e-06	1.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CETP—coronary artery disease	1.52e-06	1.94e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARGC1A—coronary artery disease	1.5e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—coronary artery disease	1.5e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SDC1—coronary artery disease	1.5e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—coronary artery disease	1.5e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6R—coronary artery disease	1.5e-06	1.91e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLCB1—coronary artery disease	1.49e-06	1.9e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—coronary artery disease	1.48e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLCB3—coronary artery disease	1.48e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—coronary artery disease	1.47e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK1—coronary artery disease	1.47e-06	1.88e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA5—coronary artery disease	1.46e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—coronary artery disease	1.46e-06	1.86e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—coronary artery disease	1.45e-06	1.85e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCA1—coronary artery disease	1.44e-06	1.84e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOB—coronary artery disease	1.43e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—P4HB—coronary artery disease	1.43e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PSMB5—coronary artery disease	1.42e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PSMA6—coronary artery disease	1.42e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	1.41e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	1.41e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—coronary artery disease	1.4e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—coronary artery disease	1.4e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GGT1—coronary artery disease	1.4e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GOT1—coronary artery disease	1.4e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—coronary artery disease	1.4e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—coronary artery disease	1.39e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—coronary artery disease	1.39e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTGF—coronary artery disease	1.38e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK1—coronary artery disease	1.38e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—coronary artery disease	1.37e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMGCR—coronary artery disease	1.37e-06	1.75e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GOT2—coronary artery disease	1.37e-06	1.75e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LPL—coronary artery disease	1.37e-06	1.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF2—coronary artery disease	1.36e-06	1.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK1—coronary artery disease	1.34e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—coronary artery disease	1.34e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—coronary artery disease	1.34e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—VCAN—coronary artery disease	1.33e-06	1.7e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDOA—coronary artery disease	1.32e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CD36—coronary artery disease	1.3e-06	1.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JAK2—coronary artery disease	1.3e-06	1.66e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPP2CA—coronary artery disease	1.29e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DCN—coronary artery disease	1.28e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—coronary artery disease	1.28e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—coronary artery disease	1.28e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—coronary artery disease	1.27e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—coronary artery disease	1.27e-06	1.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—coronary artery disease	1.26e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLCB1—coronary artery disease	1.26e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—coronary artery disease	1.25e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK1—coronary artery disease	1.25e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—coronary artery disease	1.25e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDH2—coronary artery disease	1.24e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	1.24e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK1—coronary artery disease	1.24e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—coronary artery disease	1.24e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	1.24e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—coronary artery disease	1.23e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK1—coronary artery disease	1.23e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCA1—coronary artery disease	1.22e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—coronary artery disease	1.22e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LIPC—coronary artery disease	1.21e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HBA1—coronary artery disease	1.21e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	1.21e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	1.21e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOC3—coronary artery disease	1.2e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LDLR—coronary artery disease	1.2e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—coronary artery disease	1.19e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—coronary artery disease	1.19e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOB—coronary artery disease	1.18e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—coronary artery disease	1.18e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	1.18e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GGT1—coronary artery disease	1.18e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GOT1—coronary artery disease	1.18e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGT—coronary artery disease	1.17e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCLC—coronary artery disease	1.17e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CETP—coronary artery disease	1.17e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—coronary artery disease	1.16e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SDC1—coronary artery disease	1.16e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—coronary artery disease	1.15e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—coronary artery disease	1.15e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOA1—coronary artery disease	1.14e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—coronary artery disease	1.13e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LPL—coronary artery disease	1.13e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—coronary artery disease	1.13e-06	1.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—coronary artery disease	1.1e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—coronary artery disease	1.1e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PSMA6—coronary artery disease	1.09e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PSMB5—coronary artery disease	1.09e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—coronary artery disease	1.09e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.09e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD36—coronary artery disease	1.07e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—coronary artery disease	1.07e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—coronary artery disease	1.07e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTGF—coronary artery disease	1.07e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—coronary artery disease	1.06e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—coronary artery disease	1.06e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	1.06e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMGCR—coronary artery disease	1.06e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GOT2—coronary artery disease	1.06e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	1.05e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—coronary artery disease	1.05e-06	1.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—coronary artery disease	1.04e-06	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—coronary artery disease	1.03e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—coronary artery disease	1.03e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—coronary artery disease	1.02e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOB—coronary artery disease	1e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—coronary artery disease	1e-06	1.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POMC—coronary artery disease	9.87e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—coronary artery disease	9.76e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—coronary artery disease	9.76e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLCB1—coronary artery disease	9.72e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGT—coronary artery disease	9.68e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—coronary artery disease	9.63e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—coronary artery disease	9.63e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPL—coronary artery disease	9.58e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—coronary artery disease	9.51e-07	1.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—coronary artery disease	9.5e-07	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—coronary artery disease	9.48e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—coronary artery disease	9.43e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCA1—coronary artery disease	9.43e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOA1—coronary artery disease	9.37e-07	1.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—coronary artery disease	9.35e-07	1.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GGT1—coronary artery disease	9.13e-07	1.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GOT1—coronary artery disease	9.13e-07	1.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD36—coronary artery disease	9.11e-07	1.16e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPP2CA—coronary artery disease	8.99e-07	1.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—coronary artery disease	8.92e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—coronary artery disease	8.88e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—coronary artery disease	8.84e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—coronary artery disease	8.77e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—coronary artery disease	8.7e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK1—coronary artery disease	8.67e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—coronary artery disease	8.63e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—coronary artery disease	8.6e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—coronary artery disease	8.26e-07	1.06e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—coronary artery disease	8.2e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGT—coronary artery disease	8.2e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POMC—coronary artery disease	8.15e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	8.12e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—coronary artery disease	8.09e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—coronary artery disease	8.03e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—coronary artery disease	7.98e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOA1—coronary artery disease	7.94e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—coronary artery disease	7.87e-07	1.01e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—coronary artery disease	7.85e-07	1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOB—coronary artery disease	7.75e-07	9.9e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	7.6e-07	9.72e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—coronary artery disease	7.54e-07	9.63e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—coronary artery disease	7.52e-07	9.62e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—coronary artery disease	7.43e-07	9.5e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPL—coronary artery disease	7.4e-07	9.46e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—coronary artery disease	7.28e-07	9.31e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—coronary artery disease	7.22e-07	9.23e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—coronary artery disease	7.1e-07	9.08e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD36—coronary artery disease	7.03e-07	8.98e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—coronary artery disease	7e-07	8.95e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	6.94e-07	8.87e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POMC—coronary artery disease	6.9e-07	8.82e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—coronary artery disease	6.66e-07	8.52e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—coronary artery disease	6.66e-07	8.51e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—coronary artery disease	6.5e-07	8.31e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—coronary artery disease	6.41e-07	8.19e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGT—coronary artery disease	6.33e-07	8.09e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—coronary artery disease	6.29e-07	8.04e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—coronary artery disease	6.2e-07	7.93e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—coronary artery disease	6.14e-07	7.86e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA1—coronary artery disease	6.13e-07	7.84e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—coronary artery disease	6.02e-07	7.69e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—coronary artery disease	5.5e-07	7.04e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—coronary artery disease	5.4e-07	6.9e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POMC—coronary artery disease	5.33e-07	6.81e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—coronary artery disease	4.86e-07	6.21e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—coronary artery disease	4.84e-07	6.19e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—coronary artery disease	4.64e-07	5.94e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—coronary artery disease	4.25e-07	5.43e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	4e-07	5.11e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—coronary artery disease	3.96e-07	5.06e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—coronary artery disease	3.39e-07	4.33e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—coronary artery disease	3.27e-07	4.18e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—coronary artery disease	2.77e-07	3.54e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	2.61e-07	3.34e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—coronary artery disease	2.14e-07	2.73e-06	CbGpPWpGaD
